What's New in Myeloma Research:
- Exciting times for myeloma research
An Inside Blood article about the results of endothelial cell research which expand our understanding of the biology of MMECs and of the possible paracrine and cell-to-cell interactions of endothelial and myeloma cells.
- Endothelial cells in the bone marrow of patients with multiple myeloma
Angelo Vacca, Roberto Ria, Fabrizio Semeraro, Francesca Merchionne, Mauro Coluccia, Angela Boccarelli, Claudio Scavelli, Beatrice Nico, Angela Gernone, Feliciana Battelli, Antonio Tabilio, Diego Guidolin, Maria Teresa Petrucci, Domenico Ribatti and IMF Scientific Advisor Franco Dammacco
This is the research referenced in the Inside Blood article above.
- Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24
Maurizio Chiriva-Internati, Yong Liu, Jon A. Weidanz, Fabio Grizzi, Hong You, Weiping Zhou, Klaus Bumm, Barthel Barlogie, Jawahar L. Mehta and Paul L. Hermonat
Data extend earlier studies and suggest that the rAAV-loading of DCs may be a particularly good protocol for generating CTLs against self-antigens.
- Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro
Naoya Ochiai, Ryo Uchida, Shin-ichi Fuchida, Akira Okano, Masashi Okamoto, Eishi Ashihara, Tohru Inaba, Naohisa Fujita, Hiroaki Matsubara and Chihiro Shimazaki
This is the first report that demonstrates the relationship between the N-Ras mutation in fresh myeloma cells and the effect of R115777.
- Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels
Niels W. C. J. van de Donk, Marloes M. J. Kamphuis, Berris van Kessel, IMF Scientific Advisor Henk M. Lokhorst and Andries C. Bloem
Results show that pharmacologic agents such as lovastatin or GGTase inhibitors may be useful in the treatment of multiple myeloma.
- Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance
Dharminder Chauhan, Guilan Li, Teru Hideshima, Klaus Podar, Constantine Mitsiades, Nicholas Mitsiades, Laurence Catley, Yu Tzu Tai, Toshiaki Hayashi, Reshma Shringarpure, Renate Burger, Nikhil Munshi, Yasuyuki Ohtake, Satya Saxena and Kenneth C. Anderson
Data demonstrate that Hsp27 inhibits the release of Smac, and thereby confers Dex resistance in MM cells.
- Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
David G. Maloney, Arthur J. Molina, Firoozeh Sahebi, Keith E. Stockerl-Goldstein, Brenda M. Sandmaier, William Bensinger, Barry Storer, Ute Hegenbart, George Somlo, Thomas Chauncey, Benedetto Bruno, Frederick R. Appelbaum, Karl G. Blume, Stephen J. Forman, Peter McSweeney and Rainer Storb
Despite being evaluated in elderly patients, researchers found that this 2-step approach reduced the acute toxicities of allogeneic HCT while achieving potent antitumor activities.
- Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients
Gerold Meinhardt, Farshid Dayyani, Bernd Jahrsdörfer, Joachim Baumgart, Bertold Emmerich and Ralf Schmidmaier
Treosulfan is an alkylating substance that has been used in the treatment of ovarian carcinomas for many years. It has a favourable side-effect profile even at high-dose protocols.
- Apoptotic signaling in multiple myeloma: therapeutic implications.
Chauhan D, Hideshima T, Anderson KC.
Novel agents that target the MM cell in its BM microenvironment are needed to both enhance anti-MM activity and prevent development of drug resistance.
- Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.
Ann-Hwee Lee, Neal N. Iwakoshi, Kenneth C. Anderson, and Laurie H. Glimcher
Researchers concluded that identification of compounds that target the activity of IRE1alpha/XBP-1 may yield novel therapies for the treatment of multiple myeloma and other malignancies that rely on an intact UPR. (PDF document)
- Interleukin-6-induced proliferation of human myeloma cells associated with CD45 molecules
Ishikawa H, Tsuyama N, Kawano MM
Researchers showed that IL-6 efficiently activated both signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase 1/2 (ERK1/2) in CD45- myeloma cell lines, although CD45- cells failed to proliferate in response to IL-6.
- Recent advances in understanding the pathogenesis of anemia in multiple myeloma.
Silvestris F, Tucci M, Quatraro C, Dammacco F.
Pathogenetic mechanism of anemia in MM based on persistent erythroblast cytotoxicity within the bone marrow that leads to progressive destruction of the erythroid matrix.
What's New in Clinical Trials:
(In alphabetical order)
- Cancer Trials Support Unit: A Web Based System That Offers Efficient and Effective Tools for Clinical Trials Management.
The Cancer Trials Support Unit (CTSU) is an NCI funded program to facilitate participation (by both patients and physicians) in phase III NCI sponsored Cancer treatment trials.
If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find CenterWatch and EmergingMed. The IMF has entered into partnerships with them to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute.
- Funding and Medicare Issues Still Debated by Congress
Congress is still working on funding bills and the Medicare reform legislation in hopes of finalizing both prior to a targeted mid-November recess. The appropriations bills, which should have been passed prior to the end of the fiscal year on September 30, must be finished prior to the recess. The fate and final version of the Medicare bill is uncertain.
Upcoming Seminars and Conferences:
- Tokyo Patient & Family Seminar
November 2, 2003
- Dallas Patient & Family Interactive Seminar
Baylor University Medical Center
November 7-8, 2003
- IVth International Conference on Cancer-Induced Bone Diseases
San Antonio, Texas
December 7-9, 2003
Put on by the Paget Foundation, conference will cover the spectrum of bone metastases caused by breast cancer, prostate cancer, and osteolyic lesions due to myeloma. IMF Board Member Gregory R. Mundy, MD is Conference Chair.
- IMF Patient and Family Retreat
Ft. Lauderdale, FL
January 23-25, 2004
FUNdraising Made Easy
You know you want to do something, but deciding on what to do can be confusing. The IMF can help. This year, our members really rallied 'round the cause, picked up the gauntlet, and raised a lot of money for myeloma research and programs.
We are already getting calls from new members who want to join in the effort and hold an event in 2004. Suzanne Battaglia is waiting for your call. She is here to help you plan and execute your event, so please write, call or email (SBattaglia@myeloma.org) so that you can get on our Calendar of Events!
See what you can do in your community to help further the goal of finding the cure!
Items of Interest:
- Understanding Thalidomide Therapy on the Web
Read it on the web or download and print the PDF document. Available in English, Spanish, French, German, and Italian.
- The National Cancer Institute (NCI) Office of Education and Special Initiatives is looking for patients, family caregivers, and physicians who are interested in participating in telephone focus groups and in-depth interviews. Payment will be provided to all participants.
- BANK ON A CURE®
BANK ON A CURE is an innovative and powerful concept designed to establish a method to find new treatments for multiple myeloma and other related diseases as well as the possibility of new cures, while customizing care for current patients.
- Myeloma Matrix
The Myeloma Matrix provides updated information about drugs beginning with pre-clinical developments and tracks drugs as they proceed through Phases I III of clinical trials, drugs that have been FDA approved, and information on trials that are being conducted by NCI- sponsored cooperative groups as well as other myeloma study groups. The online version is updated regularly. If you would like to have a printed copy, call the toll-free hotline (800) 452-2873.
- International Prognostic Index
The International Myeloma Foundation is proud to sponsor the International Prognostic Index (IPI) Classification for Multiple Myeloma. Nearly twenty myeloma institutions from around the world are collaborating to create an updated staging system for multiple myeloma.
- NexCura Cancer Profiler
The Cancer Profiler is a free service (no hidden fees or charges). Its tools provide you with information specific to your cancer diagnosis to help you make more informed treatment decisions along with your physician.
- Expert Opinions on Multiple Myeloma
A multimedia, CME-accredited program for physicians with the chance to see world-renowned myeloma specialists sharing their knowledge, discussing treatment choices, and comparing their perspectives on controversial issues in multiple myeloma and related diseases.
- Myeloma At The Movies
It has been our goal to bring our Patient & Family Seminars to people around the country who might not be able to attend an actual meeting, so we have set up a video lending library.
- HealthTalk's Multiple Myeloma Education Network
Put this site in your favorites folder.
Be Part of the Cure!
Many of the internet's most popular merchants will donate a portion of your purchases to the IMF if you enter their sites using the links on our Shop For The IMF page. You can also use the special shortcut URLs listed below:
So, Be Part of the Cure by using these links to the same get great service and low prices you're used to while helping support the IMF!
Help Us Help Others...
As a non-profit organization, the IMF is completely dependent on the support of our members. Please consider showing your support by making a tax-deductible donation today. Donations in honor of a friend or family member make great gifts and are a wonderful way to celebrate a special occasion. You can donate online or by calling the IMF at (800) 452-CURE. We sincerely thank you for your support.
View Back Issues Online...
New to the IMF Myeloma Minute? See what you've been missing by viewing previous issues online!
To unsubscribe from the Myeloma Minute, click here
Tell A Friend...
The Myeloma Minute is a great way to stay abreast of the latest developments within the myeloma community. We hope you'll share this information with friends, family members and physicians and encourage them to sign up for their own copy by forwarding this message. New users can register by clicking here.